Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12412822,half-life,"Plasma levels were maintained at a plateau between 1 and 6 hours postdose, then decreased with a half-life of approximately 3 hours.",Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412822/),h,3,11570,DB00315,Zolmitriptan
,22023340,di,"Furthermore, it had a low in-vitro and in-vivo disintegration time (11 s) and it reached 100% of drug release within 30 s.",Fast relief from migraine attacks using fast-disintegrating sublingual zolmitriptan tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22023340/),s,11,12387,DB00315,Zolmitriptan
,26189757,total chromatographic run time,The total chromatographic run time was 2.5 min.,Systematic evaluation of matrix effect and cross-talk-free method for simultaneous determination of zolmitriptan and N-desmethyl zolmitriptan in human plasma: a sensitive LC-MS/MS method validation and its application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26189757/),min,2.5,14815,DB00315,Zolmitriptan
,25771739,cumulative penetration amount,"A sufficient cumulative penetration amount of zolmitriptan (258.5 ± 26.9 μg/cm(2) in 24 h) was achieved by the formulation of 4% zolmitriptan, 10% Azone, and adhesive of DURO-TAK® 87-4098.",Drug in Adhesive Patch of Zolmitriptan: Formulation and In vitro /In vivo Correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25771739/),[μg] / [cm(2],258.5,18924,DB00315,Zolmitriptan
,25771739,absolute bioavailability,The results revealed that the absolute bioavailability was about 63%.,Drug in Adhesive Patch of Zolmitriptan: Formulation and In vitro /In vivo Correlation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25771739/),%,63,18925,DB00315,Zolmitriptan
,25488888,Фmax1B,"Our calculations showed that Фmax1B and Фmax1D were relatively high at 32.0-89.4% and 68.4-96.2%, respectively, suggesting that it is likely that a high occupancy is necessary to attain the clinical effect.",Theory-based analysis of clinical efficacy of triptans using receptor occupancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488888/),%,32.0-89.4,43895,DB00315,Zolmitriptan
,25488888,Фmax,"Our calculations showed that Фmax1B and Фmax1D were relatively high at 32.0-89.4% and 68.4-96.2%, respectively, suggesting that it is likely that a high occupancy is necessary to attain the clinical effect.",Theory-based analysis of clinical efficacy of triptans using receptor occupancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488888/),%,32.0-89.4,43896,DB00315,Zolmitriptan
,9205817,oral bioavailability,Mean +/- s.d. oral bioavailability was 0.49 +/- 0.24 (0.38 +/- 0.16 in men and 0.60 +/- 0.28 in women).,The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205817/),,0.49,46106,DB00315,Zolmitriptan
,9205817,oral bioavailability,Mean +/- s.d. oral bioavailability was 0.49 +/- 0.24 (0.38 +/- 0.16 in men and 0.60 +/- 0.28 in women).,The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205817/),,0.38,46107,DB00315,Zolmitriptan
,9205817,oral bioavailability,Mean +/- s.d. oral bioavailability was 0.49 +/- 0.24 (0.38 +/- 0.16 in men and 0.60 +/- 0.28 in women).,The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205817/),,0.60,46108,DB00315,Zolmitriptan
,9205817,CL,"Mean +/- s.d. values for CL, V2 and t1/2,z after i.v. dosing (all subjects) were 8.7 +/- 1.7 ml min-1 kg-1, 122 +/- 321 and 2.30 +/- 0.59 h respectively.",The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205817/),[ml] / [kg·min],8.7,46109,DB00315,Zolmitriptan
,9205817,V2,"Mean +/- s.d. values for CL, V2 and t1/2,z after i.v. dosing (all subjects) were 8.7 +/- 1.7 ml min-1 kg-1, 122 +/- 321 and 2.30 +/- 0.59 h respectively.",The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205817/),h,122,46110,DB00315,Zolmitriptan
,9205817,t1/2,"Mean +/- s.d. values for CL, V2 and t1/2,z after i.v. dosing (all subjects) were 8.7 +/- 1.7 ml min-1 kg-1, 122 +/- 321 and 2.30 +/- 0.59 h respectively.",The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205817/),h,122,46111,DB00315,Zolmitriptan
,29124986,ve,"Optimized ZT-transfersome formulation containing 82.74 mg of lecithin (X1), 98.37 mg of zolmitriptan (X2) and 32.2 mg of Tween 80 (X3) and had vesicle size of 93.3 nm, flexibility index of 20.25 and drug release regression coefficient of 0.992.",Development of zolmitriptan transfersomes by Box-Behnken design for nasal delivery: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124986/),,93.3,58436,DB00315,Zolmitriptan
,29124986,flexibility,"Optimized ZT-transfersome formulation containing 82.74 mg of lecithin (X1), 98.37 mg of zolmitriptan (X2) and 32.2 mg of Tween 80 (X3) and had vesicle size of 93.3 nm, flexibility index of 20.25 and drug release regression coefficient of 0.992.",Development of zolmitriptan transfersomes by Box-Behnken design for nasal delivery: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124986/),,20.25,58437,DB00315,Zolmitriptan
<,28741429,tmax,"Median tmax was <20 min, comparable to subcutaneous sumatriptan.",Rapid systemic delivery of zolmitriptan using an adhesive dermally applied microarray. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741429/),min,20,75703,DB00315,Zolmitriptan
,26242873,occup,"For Ф1D, it was indicated that all triptans obtained an occupancy of 80% or higher at maximum.",Theoretical analysis of headache recurrence in patients administered triptans for migraine based on receptor occupancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242873/),%,80,83156,DB00315,Zolmitriptan
,9071266,absolute oral bioavailability,"It is rapidly absorbed, with 75% of maximal plasma concentration (Cmax) attained within 1 hour and good absolute oral bioavailability (approximately 40%).",311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9071266/),%,40,86095,DB00315,Zolmitriptan
,28618340,flow rate,A simple isocratic separation mode was used with a mobile phase consisted of acetonitrile and 10mM phosphate buffer adjusted to pH 3.0 (20:80; v/v) at flow rate 1.0mLmin-1.,Fast and efficient zirconia-based reversed phase chromatography for selective determination of triptans in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618340/),1/[mlmin],1.0,86345,DB00315,Zolmitriptan
,28618340,detection limits,The linearity range obtained for the developed HPLC method was 15-2000ngmL-1 with detection limits of 4.8- 6.2ngmL-1 for all the studied triptans.,Fast and efficient zirconia-based reversed phase chromatography for selective determination of triptans in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618340/),1/[ngml],4.8- 6.2,86346,DB00315,Zolmitriptan
,11422001,AUC,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[h·ng] / [ml],483,90332,DB00315,Zolmitriptan
,11422001,AUC,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[h·ng] / [ml],352,90333,DB00315,Zolmitriptan
,11422001,oral clearance,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[l] / [h],26.6,90334,DB00315,Zolmitriptan
,11422001,oral clearance,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[l] / [h],36.6,90335,DB00315,Zolmitriptan
,11422001,half-life,"Mean half-life was longer (4.22 +/- 0.78 vs 3.41 +/- 0.45 h, P = 0.0002) after coadministration with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),h,4.22,90336,DB00315,Zolmitriptan
,11422001,half-life,"Mean half-life was longer (4.22 +/- 0.78 vs 3.41 +/- 0.45 h, P = 0.0002) after coadministration with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),h,3.41,90337,DB00315,Zolmitriptan
,31593739,Amount of drug,"Amount of drug in the plasma from the test formulation, standard marketed drug (Zolmist) and standard drug solution was found to be 41.37 ± 2.31, 34.76 ± 4.22 and 23.74 ± 2.42 ng/ml at 10 min respectively, which indicated significantly (p < 0.05) greater amount of drug being delivered from the test formulation compared to the both standard groups.",Pharmacokinetic study and brain tissue analysis of Zolmitriptan loaded chitosan nanoparticles in rats by LC-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31593739/),[ng] / [ml],41.37,92442,DB00315,Zolmitriptan
,31593739,Amount of drug,"Amount of drug in the plasma from the test formulation, standard marketed drug (Zolmist) and standard drug solution was found to be 41.37 ± 2.31, 34.76 ± 4.22 and 23.74 ± 2.42 ng/ml at 10 min respectively, which indicated significantly (p < 0.05) greater amount of drug being delivered from the test formulation compared to the both standard groups.",Pharmacokinetic study and brain tissue analysis of Zolmitriptan loaded chitosan nanoparticles in rats by LC-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31593739/),[ng] / [ml],34.76,92443,DB00315,Zolmitriptan
,31593739,Amount of drug,"Amount of drug in the plasma from the test formulation, standard marketed drug (Zolmist) and standard drug solution was found to be 41.37 ± 2.31, 34.76 ± 4.22 and 23.74 ± 2.42 ng/ml at 10 min respectively, which indicated significantly (p < 0.05) greater amount of drug being delivered from the test formulation compared to the both standard groups.",Pharmacokinetic study and brain tissue analysis of Zolmitriptan loaded chitosan nanoparticles in rats by LC-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31593739/),[ng] / [ml],23.74,92444,DB00315,Zolmitriptan
,12136370,half-lives,Mean zolmitriptan and 183C91 half-lives were around 2.5 h for both populations.,The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12136370/),h,2.5,93313,DB00315,Zolmitriptan
,9431839,t1/2,Propranolol increased mean zolmitriptan Cmax and AUC by 56% and 37% respectively; mean t1/2 was prolonged from 3.1 to 4.0 h.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),h,3.1,97619,DB00315,Zolmitriptan
,9431839,t1/2,Propranolol increased mean zolmitriptan Cmax and AUC by 56% and 37% respectively; mean t1/2 was prolonged from 3.1 to 4.0 h.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),h,4.0,97620,DB00315,Zolmitriptan
,9431839,AUC ratio (AUCm/AUCp),Mean Cmax and AUC of the pharmacologically active N-desmethyl metabolite were reduced by 24% and 11% respectively and the metabolite:parent AUC ratio (AUCm/AUCp) fell from 0.46 to 0.26.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),,0.46,97621,DB00315,Zolmitriptan
,9431839,AUC ratio (AUCm/AUCp),Mean Cmax and AUC of the pharmacologically active N-desmethyl metabolite were reduced by 24% and 11% respectively and the metabolite:parent AUC ratio (AUCm/AUCp) fell from 0.46 to 0.26.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),,0.26,97622,DB00315,Zolmitriptan
,9431839,AUCm/AUCp,Mean Cmax and AUC for the inactive indole acetic acid metabolite were both reduced by 13% and AUCm/AUCp from 1.04 to 0.59.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),,1.04,97623,DB00315,Zolmitriptan
,9431839,AUCm/AUCp,Mean Cmax and AUC for the inactive indole acetic acid metabolite were both reduced by 13% and AUCm/AUCp from 1.04 to 0.59.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),,0.59,97624,DB00315,Zolmitriptan
,9431839,peak rises,A small pressor effect of short duration was observed following zolmitriptan with mean peak rises of 13 and 11 mmHg in systolic and diastolic pressures respectively; propranolol had no effect on the pressor response.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),mmhg,13,97625,DB00315,Zolmitriptan
,9431839,peak rises,A small pressor effect of short duration was observed following zolmitriptan with mean peak rises of 13 and 11 mmHg in systolic and diastolic pressures respectively; propranolol had no effect on the pressor response.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),mmhg,11,97626,DB00315,Zolmitriptan
,12412823,t1/2,Mean t1/2 for zolmitriptan and 183C91 was approximately 3 hours.,"Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412823/),h,3,98973,DB00315,Zolmitriptan
,22722326,flow rate,"A mixture of methanol-20 mM ammonium acetate-formic acid (60:40:0.1, v/v/v) was used as mobile phase at a flow rate of 0.3 mL/min.","Determination of zolmitriptan and its primary metabolite, n-desmethy-zolmitriptan, in rat plasma by LC-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722326/),[ml] / [min],0.3,116787,DB00315,Zolmitriptan
,22722326,ch,The chromatographic run time of each sample was 3.0 min.,"Determination of zolmitriptan and its primary metabolite, n-desmethy-zolmitriptan, in rat plasma by LC-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722326/),min,3.0,116788,DB00315,Zolmitriptan
,22722326,run time,The chromatographic run time of each sample was 3.0 min.,"Determination of zolmitriptan and its primary metabolite, n-desmethy-zolmitriptan, in rat plasma by LC-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722326/),min,3.0,116789,DB00315,Zolmitriptan
,10357516,half-life,The area under the curve (AUC) and highest observed plasma concentration (Cmax) of zolmitriptan were similar in both age groups; the half-life was 3.01 hours in adolescents versus 3.75 hours in adults.,A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10357516/),h,3.01,126552,DB00315,Zolmitriptan
,10357516,half-life,The area under the curve (AUC) and highest observed plasma concentration (Cmax) of zolmitriptan were similar in both age groups; the half-life was 3.01 hours in adolescents versus 3.75 hours in adults.,A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10357516/),h,3.75,126553,DB00315,Zolmitriptan
,9833595,absolute oral bioavailability,"The mean (s.d.) absolute oral bioavailability was 0.41 (0.14 and 0.40) 0.09 after 2.5 mg and 0.48+/-0.14 and 0.36+/-0.07 after 5 mg in women and men, respectively.",The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833595/),,0.41,133173,DB00315,Zolmitriptan
,9833595,absolute oral bioavailability,"The mean (s.d.) absolute oral bioavailability was 0.41 (0.14 and 0.40) 0.09 after 2.5 mg and 0.48+/-0.14 and 0.36+/-0.07 after 5 mg in women and men, respectively.",The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833595/),,0.40,133174,DB00315,Zolmitriptan
,9833595,absolute oral bioavailability,"The mean (s.d.) absolute oral bioavailability was 0.41 (0.14 and 0.40) 0.09 after 2.5 mg and 0.48+/-0.14 and 0.36+/-0.07 after 5 mg in women and men, respectively.",The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833595/),,0.09,133175,DB00315,Zolmitriptan
,9833595,absolute oral bioavailability,"The mean (s.d.) absolute oral bioavailability was 0.41 (0.14 and 0.40) 0.09 after 2.5 mg and 0.48+/-0.14 and 0.36+/-0.07 after 5 mg in women and men, respectively.",The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833595/),,0.48,133176,DB00315,Zolmitriptan
,9833595,absolute oral bioavailability,"The mean (s.d.) absolute oral bioavailability was 0.41 (0.14 and 0.40) 0.09 after 2.5 mg and 0.48+/-0.14 and 0.36+/-0.07 after 5 mg in women and men, respectively.",The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833595/),,0.36,133177,DB00315,Zolmitriptan
,9833595,AUC,"Mean (+/-s.d.) AUC was 32.7+/-10.1 and 60.2+/-26.8 ng ml(-1) h after 5 mg in men and women, respectively (95% CI for ratio 0.43-0.77).",The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833595/),[h·ng] / [ml],32.7,133178,DB00315,Zolmitriptan
,9833595,AUC,"Mean (+/-s.d.) AUC was 32.7+/-10.1 and 60.2+/-26.8 ng ml(-1) h after 5 mg in men and women, respectively (95% CI for ratio 0.43-0.77).",The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833595/),[h·ng] / [ml],60.2,133179,DB00315,Zolmitriptan
,9833595,AUC,"After 2.5 mg mean (+/-s.d.) AUC was 18.4+/-5.4 and 23.1+/-9.9 ng ml(-1) h in men and women, respectively (95% CI for ratio 0.61-1.09).",The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833595/),[h·ng] / [ml],18.4,133180,DB00315,Zolmitriptan
,9833595,AUC,"After 2.5 mg mean (+/-s.d.) AUC was 18.4+/-5.4 and 23.1+/-9.9 ng ml(-1) h in men and women, respectively (95% CI for ratio 0.61-1.09).",The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833595/),[h·ng] / [ml],23.1,133181,DB00315,Zolmitriptan
,29772224,absolute bioavailability,Pharmacokinetic studies showed that the ADAM 1.9-mg zolmitriptan was delivered with high efficiency (85%) and high absolute bioavailability (77%).,Pharmacokinetics and Skin Tolerability of Intracutaneous Zolmitriptan Delivery in Swine Using Adhesive Dermally Applied Microarray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772224/),%,77,139760,DB00315,Zolmitriptan
,29772224,Tmax,"Furthermore, in vivo evaluation showed a rapid systemic absorption with a median Tmax of 15 min.",Pharmacokinetics and Skin Tolerability of Intracutaneous Zolmitriptan Delivery in Swine Using Adhesive Dermally Applied Microarray. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772224/),min,15,139761,DB00315,Zolmitriptan
,29772224,depth of microprojection penetration,Skin biopsies of the treatment sites showed a mean depth of microprojection penetration of 105.4 ± 3.6 μm.,Pharmacokinetics and Skin Tolerability of Intracutaneous Zolmitriptan Delivery in Swine Using Adhesive Dermally Applied Microarray. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29772224/),μm,105.4,139762,DB00315,Zolmitriptan
,16413836,run time,The instrument parameters were optimized to obtain 3.0 min run time.,Determination of zolmitriptan in human plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413836/),min,3.0,145075,DB00315,Zolmitriptan
,16413836,flow rate,"The mobile phase consisted of acetonitrile-water-formic acid (70:30:0.5), at a flow rate of 0.5 ml/min.",Determination of zolmitriptan in human plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413836/),[ml] / [min],0.5,145076,DB00315,Zolmitriptan
,9542478,half-life,Zolmitriptan half-life was 2.8 to 3.6 hours in the elderly compared with 2.7 to 2.9 hours in young adults.,The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542478/),h,2.8 to 3.6,147965,DB00315,Zolmitriptan
,9542478,half-life,Zolmitriptan half-life was 2.8 to 3.6 hours in the elderly compared with 2.7 to 2.9 hours in young adults.,The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542478/),h,2.7 to 2.9,147966,DB00315,Zolmitriptan
,16199375,globule size,ZME were transparent and stable with mean globule size of 35 +/- 25 nm and zeta potential of - 38- - 52 mV.,Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16199375/),nm,35,150559,DB00315,Zolmitriptan
,16199375,brain/blood uptake ratios,"Following intranasal administrations of zolmitriptan mucoadhesive microemulsion (ZMME), ZME, Zolmitriptan solution (ZS) and intravenous administration of ZS, brain/blood uptake ratios at 0.50 h were found to be 0.70, 0.56, 0.27 and 0.13, respectively, indicating effective brain-targeting following intranasal administration of ZMME.",Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16199375/),,0.70,150560,DB00315,Zolmitriptan
,16199375,brain/blood uptake ratios,"Following intranasal administrations of zolmitriptan mucoadhesive microemulsion (ZMME), ZME, Zolmitriptan solution (ZS) and intravenous administration of ZS, brain/blood uptake ratios at 0.50 h were found to be 0.70, 0.56, 0.27 and 0.13, respectively, indicating effective brain-targeting following intranasal administration of ZMME.",Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16199375/),,0.56,150561,DB00315,Zolmitriptan
,16199375,brain/blood uptake ratios,"Following intranasal administrations of zolmitriptan mucoadhesive microemulsion (ZMME), ZME, Zolmitriptan solution (ZS) and intravenous administration of ZS, brain/blood uptake ratios at 0.50 h were found to be 0.70, 0.56, 0.27 and 0.13, respectively, indicating effective brain-targeting following intranasal administration of ZMME.",Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16199375/),,0.27,150562,DB00315,Zolmitriptan
,16199375,brain/blood uptake ratios,"Following intranasal administrations of zolmitriptan mucoadhesive microemulsion (ZMME), ZME, Zolmitriptan solution (ZS) and intravenous administration of ZS, brain/blood uptake ratios at 0.50 h were found to be 0.70, 0.56, 0.27 and 0.13, respectively, indicating effective brain-targeting following intranasal administration of ZMME.",Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16199375/),,0.13,150563,DB00315,Zolmitriptan
,9399013,oral bioavailability,In healthy volunteers it is rapidly and extensively absorbed and has favorable oral bioavailability (approximately 40%) which is not affected by concomitant food intake.,The clinical pharmacokinetics of zolmitriptan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9399013/),%,40,154086,DB00315,Zolmitriptan
,9399013,elimination half lives,"The elimination half lives of zolmitriptan and its metabolites are similar, approximately 3 h.",The clinical pharmacokinetics of zolmitriptan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9399013/),h,3,154087,DB00315,Zolmitriptan
,27757013,terminal elimination half-life in blood,Frovatriptan is a second-generation triptan with a longer terminal elimination half-life in blood than other triptans (~26 hours).,Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27757013/),h,26,182748,DB00315,Zolmitriptan
,10637423,limits of detection (LOD),The limits of detection (LOD) for the method were 250 pg/mL for sumatriptan and 100 pg/mL for the remaining analytes based on a signal-to-noise ratio of 3.,"Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637423/),[pg] / [ml],250,185085,DB00315,Zolmitriptan
,10637423,limits of detection (LOD),The limits of detection (LOD) for the method were 250 pg/mL for sumatriptan and 100 pg/mL for the remaining analytes based on a signal-to-noise ratio of 3.,"Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637423/),[pg] / [ml],100,185086,DB00315,Zolmitriptan
,10637423,signal-to-noise ratio,The limits of detection (LOD) for the method were 250 pg/mL for sumatriptan and 100 pg/mL for the remaining analytes based on a signal-to-noise ratio of 3.,"Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637423/),,3,185087,DB00315,Zolmitriptan
,9088582,AUC,"After the last 10 mg dose, mean dosing interval zolmitriptan AUC was 80.3 ng ml-1 h compared with 86.5 ng ml-1 h after the single 10 mg dose (95% CI for ratio 0.76-1.13).",The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088582/),[h·ng] / [ml],80.3,199821,DB00315,Zolmitriptan
,9088582,AUC,"After the last 10 mg dose, mean dosing interval zolmitriptan AUC was 80.3 ng ml-1 h compared with 86.5 ng ml-1 h after the single 10 mg dose (95% CI for ratio 0.76-1.13).",The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088582/),[h·ng] / [ml],86.5,199822,DB00315,Zolmitriptan
,8838441,tmax,Median tmax was 2-4 h although 50-85% of eventual Cmax was attained within 1 h.,The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838441/),h,2-4,205195,DB00315,Zolmitriptan
,8838441,t1/2,The t1/2 was 2.5-3 h with a high apparent plasma clearance (CL/F > 2000 ml min-1) and apparent volume of distribution (Vz/F) of 400-500 l.,The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838441/),h,2.5-3,205196,DB00315,Zolmitriptan
>,8838441,apparent plasma clearance (CL/F,The t1/2 was 2.5-3 h with a high apparent plasma clearance (CL/F > 2000 ml min-1) and apparent volume of distribution (Vz/F) of 400-500 l.,The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838441/),[ml] / [min],2000,205197,DB00315,Zolmitriptan
,8838441,apparent volume of distribution (Vz/F),The t1/2 was 2.5-3 h with a high apparent plasma clearance (CL/F > 2000 ml min-1) and apparent volume of distribution (Vz/F) of 400-500 l.,The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838441/),l,400-500,205198,DB00315,Zolmitriptan
,22743338,limits of detection,"The applied HPLC-MS/MS method allowed low limits of detection, as calculated from calibration curves, of 6.6 and 24.4 ng/mL for water matrix and rat blood extracts, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[ng] / [ml],6.6,206371,DB00315,Zolmitriptan
,22743338,limits of detection,"The applied HPLC-MS/MS method allowed low limits of detection, as calculated from calibration curves, of 6.6 and 24.4 ng/mL for water matrix and rat blood extracts, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[ng] / [ml],24.4,206372,DB00315,Zolmitriptan
,22743338,terminal half-life,"The intravenous infusion of 20 μg zolmitriptan to male Sprague-Dawley rats produced blood concentrations ranging from 9.4±0.7 to 1.24±0.07 μg/mL within 10 h, with a terminal half-life of 3.4±0.2h.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),h,3.4,206373,DB00315,Zolmitriptan
,22743338,CSF,"One hour after zolmitriptan intravenous infusion or nasal administration, its CSF concentrations were 0.0539±0.0016 and 0.0453±0.0012 μg/mL, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[μg] / [ml],0.0539,206374,DB00315,Zolmitriptan
,22743338,CSF,"One hour after zolmitriptan intravenous infusion or nasal administration, its CSF concentrations were 0.0539±0.0016 and 0.0453±0.0012 μg/mL, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[μg] / [ml],0.0453,206375,DB00315,Zolmitriptan
,22743338,concentrations,"One hour after zolmitriptan intravenous infusion or nasal administration, its CSF concentrations were 0.0539±0.0016 and 0.0453±0.0012 μg/mL, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[μg] / [ml],0.0539,206376,DB00315,Zolmitriptan
,22743338,concentrations,"One hour after zolmitriptan intravenous infusion or nasal administration, its CSF concentrations were 0.0539±0.0016 and 0.0453±0.0012 μg/mL, respectively.",Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22743338/),[μg] / [ml],0.0453,206377,DB00315,Zolmitriptan
,15137991,flow rate,"HPLC separation was carried out by reversed phase chromatography with a mobile phase composed of 0.05% (v/v) triethylamine in water(adjusting to pH 2.75 with 85% phosphoric acid) and acetonitrile (92:8, v/v), pumped at flow rate of 1.5 ml/min.",High-performance liquid chromatographic analysis of zolmitriptan in human plasma using fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15137991/),[ml] / [min],1.5,219445,DB00315,Zolmitriptan
,15137991,limit of detection (LOD),"The values of the limit of detection (LOD) and limit of quantification (LOQ) were 20 and 40 pg, respectively.",High-performance liquid chromatographic analysis of zolmitriptan in human plasma using fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15137991/),pg,20,219446,DB00315,Zolmitriptan
,15137991,limit of quantification (LOQ),"The values of the limit of detection (LOD) and limit of quantification (LOQ) were 20 and 40 pg, respectively.",High-performance liquid chromatographic analysis of zolmitriptan in human plasma using fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15137991/),pg,40,219447,DB00315,Zolmitriptan
,28581633,apparent volume of distribution,"The estimated typical apparent volume of distribution and clearance of zolmitriptan were 136 L and 121 L/h, respectively, with 56.5% and 42.6% between-subject variability, respectively.",Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28581633/),l,136,226999,DB00315,Zolmitriptan
,28581633,clearance,"The estimated typical apparent volume of distribution and clearance of zolmitriptan were 136 L and 121 L/h, respectively, with 56.5% and 42.6% between-subject variability, respectively.",Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28581633/),[l] / [h],121,227000,DB00315,Zolmitriptan
,28581633,clearance,"The estimated typical apparent volume of distribution and clearance of zolmitriptan were 136 L and 121 L/h, respectively, with 56.5% and 42.6% between-subject variability, respectively.",Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28581633/),%,56,227001,DB00315,Zolmitriptan
,27128792,absolute bioavailability,The absolute bioavailability of zolmitriptan is about 40% for oral administration; due to hepatic first metabolism.,"Trans-nasal zolmitriptan novasomes: in-vitro preparation, optimization and in-vivo evaluation of brain targeting efficiency. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128792/),%,40,253889,DB00315,Zolmitriptan
,27128792,zeta potential,"This formulation showed zolmitriptan entrapment of 92.94%, particle size of 149.9 nm, zeta potential of -55.57 mV, and released 48.43% zolmitriptan after 2 h.","Trans-nasal zolmitriptan novasomes: in-vitro preparation, optimization and in-vivo evaluation of brain targeting efficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128792/),m,55.57,253890,DB00315,Zolmitriptan
,30919700,vesicle size (VS),"Results: The vesicles revealed vesicle size (VS) ranging from 133.1 to 851.3 nm, zeta potential (ZP) -43.8 to -82.8 mV, entrapment efficiency (EE%) from 66.7 to 88.7%, and Zt release after 4 h up to 67%.",Preparation and evaluation of optimized zolmitriptan niosomal emulgel. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919700/),nm,133.1 to 851.3,262761,DB00315,Zolmitriptan
,30919700,entrapment efficiency (EE%),"Results: The vesicles revealed vesicle size (VS) ranging from 133.1 to 851.3 nm, zeta potential (ZP) -43.8 to -82.8 mV, entrapment efficiency (EE%) from 66.7 to 88.7%, and Zt release after 4 h up to 67%.",Preparation and evaluation of optimized zolmitriptan niosomal emulgel. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919700/),%,66.7 to 88.7,262762,DB00315,Zolmitriptan
,30919700,VS,"Optimized niosomal formulation (F11) depicted the smallest VS (133.1 nm), highest EE (88.7%), high ZP (-80.6 mV) and satisfactory release after 4 h (61.5%).",Preparation and evaluation of optimized zolmitriptan niosomal emulgel. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919700/),nm,133.1,262763,DB00315,Zolmitriptan
,30919700,drug,There was a significant difference (p <.05) in drug permeation after 8 h for niosomal F11(460.98 ug/cm2) and niosomal F11 loaded Emulgel (336.92 ug/cm2) compared to plain Zt loaded emulgel (160.83 ug/cm2).,Preparation and evaluation of optimized zolmitriptan niosomal emulgel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919700/),[ug] / [cm2],460.98,262764,DB00315,Zolmitriptan
,30919700,drug,There was a significant difference (p <.05) in drug permeation after 8 h for niosomal F11(460.98 ug/cm2) and niosomal F11 loaded Emulgel (336.92 ug/cm2) compared to plain Zt loaded emulgel (160.83 ug/cm2).,Preparation and evaluation of optimized zolmitriptan niosomal emulgel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919700/),[ug] / [cm2],336.92,262765,DB00315,Zolmitriptan
,30919700,permeation,There was a significant difference (p <.05) in drug permeation after 8 h for niosomal F11(460.98 ug/cm2) and niosomal F11 loaded Emulgel (336.92 ug/cm2) compared to plain Zt loaded emulgel (160.83 ug/cm2).,Preparation and evaluation of optimized zolmitriptan niosomal emulgel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919700/),[ug] / [cm2],460.98,262766,DB00315,Zolmitriptan
,30919700,permeation,There was a significant difference (p <.05) in drug permeation after 8 h for niosomal F11(460.98 ug/cm2) and niosomal F11 loaded Emulgel (336.92 ug/cm2) compared to plain Zt loaded emulgel (160.83 ug/cm2).,Preparation and evaluation of optimized zolmitriptan niosomal emulgel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919700/),[ug] / [cm2],336.92,262767,DB00315,Zolmitriptan
,30919700,permeation,There was a significant difference (p <.05) in drug permeation after 8 h for niosomal F11(460.98 ug/cm2) and niosomal F11 loaded Emulgel (336.92 ug/cm2) compared to plain Zt loaded emulgel (160.83 ug/cm2).,Preparation and evaluation of optimized zolmitriptan niosomal emulgel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30919700/),[ug] / [cm2],160.83,262768,DB00315,Zolmitriptan
,31274014,MMA,MDI formulation prepared with HFA 134a propellant was found to have the lowest MMAD (3.47 ± 0.65) with GSD of 2.3 ± 0.4.,In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31274014/),,3,266709,DB00315,Zolmitriptan
,31274014,FPF,"It also had the highest FPF (41.9), ED (89.26 ± 2.35) with dispersibility of 46.9%.",In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31274014/),,41.9,266710,DB00315,Zolmitriptan
,31274014,FPF,"It also had the highest FPF (41.9), ED (89.26 ± 2.35) with dispersibility of 46.9%.",In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31274014/),,89.26,266711,DB00315,Zolmitriptan
,31274014,dispersibility,"It also had the highest FPF (41.9), ED (89.26 ± 2.35) with dispersibility of 46.9%.",In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31274014/),%,46.9,266712,DB00315,Zolmitriptan
,31274014,Tmax,"This formulation, when applied to rats, resulted in faster Tmax (27 ± 5 min) with higher Cmax (1236 ± 116 ng/mL) and AUC(0-12) (3375 ± 482 ng/mL·h) over the oral tablet.",In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31274014/),min,27,266713,DB00315,Zolmitriptan
,31274014,Cmax,"This formulation, when applied to rats, resulted in faster Tmax (27 ± 5 min) with higher Cmax (1236 ± 116 ng/mL) and AUC(0-12) (3375 ± 482 ng/mL·h) over the oral tablet.",In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31274014/),[ng] / [ml],1236,266714,DB00315,Zolmitriptan
,31274014,AUC(0-12),"This formulation, when applied to rats, resulted in faster Tmax (27 ± 5 min) with higher Cmax (1236 ± 116 ng/mL) and AUC(0-12) (3375 ± 482 ng/mL·h) over the oral tablet.",In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31274014/),[ng] / [h·ml],3375,266715,DB00315,Zolmitriptan
,31274014,relative bioavailability,Its relative bioavailability was 72.7% which was 1.25 times higher than the oral tablet relative bioavailability.,In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31274014/),%,72.7,266716,DB00315,Zolmitriptan
